Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SM-19
- Development stage
- Preclinical
- Lead developer
- Skymount Medical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**SM-19** is an investigational oral combination of repurposed FDA-approved therapies developed for early treatment of COVID-19 in non-hospitalized adults. It was identified through Louisiana State University's DeepDrug artificial-intelligence platform and was reported to target SARS-CoV-2 viral entry, fusion, and replication through an undisclosed multi-drug strategy. Preclinical cell and animal studies reportedly showed reduced viral load; the active ingredients, their individual targets, doses, and final pharmaceutical presentation have not been publicly disclosed. ([lsu.edu](https://www.lsu.edu/research/news/2021/0811-skymount-human-trials.php))
Beyond the preview
Go deeper on SM-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SM-19.